Published in Blood on February 09, 2006
Insights into the manifestations, outcomes, and mechanisms of leukemogenesis in Down syndrome. Blood (2009) 1.84
Natural history of transient myeloproliferative disorder clinically diagnosed in Down syndrome neonates: a report from the Children's Oncology Group Study A2971. Blood (2011) 1.81
Altered hematopoiesis in trisomy 21 as revealed through in vitro differentiation of isogenic human pluripotent cells. Proc Natl Acad Sci U S A (2012) 1.62
GATA1-mutant clones are frequent and often unsuspected in babies with Down syndrome: identification of a population at risk of leukemia. Blood (2013) 1.60
Treatment and prognostic impact of transient leukemia in neonates with Down syndrome. Blood (2008) 1.56
The megakaryocyte lineage originates from hemangioblast precursors and is an integral component both of primitive and of definitive hematopoiesis. Blood (2006) 1.48
Trisomy 21 enhances human fetal erythro-megakaryocytic development. Blood (2008) 1.47
The landscape of somatic mutations in Down syndrome-related myeloid disorders. Nat Genet (2013) 1.31
Down syndrome and malignancies: a unique clinical relationship: a paper from the 2008 william beaumont hospital symposium on molecular pathology. J Mol Diagn (2009) 1.29
Cardiomyopathy in children with Down syndrome treated for acute myeloid leukemia: a report from the Children's Oncology Group Study POG 9421. J Clin Oncol (2008) 1.15
Malignancy in children with trisomy 21. Oncologist (2009) 1.12
Haematology of Down syndrome. Arch Dis Child Fetal Neonatal Ed (2007) 1.11
Hematopoietic disorders in Down syndrome. Int J Clin Exp Pathol (2008) 1.09
The prenatal origins of cancer. Nat Rev Cancer (2014) 1.09
Myeloid leukemia in Down syndrome. Crit Rev Oncog (2011) 0.99
Hematological disorders and leukemia in children with Down syndrome. Eur J Pediatr (2011) 0.95
Stochastic dynamics and the evolution of mutations in stem cells. BMC Biol (2011) 0.95
Use of the International System for Human Cytogenetic Nomenclature (ISCN). Blood (2006) 0.91
Transient leukemia in down syndrome: report of two cases with review of literature. Indian J Hematol Blood Transfus (2011) 0.85
Transient myeloproliferative disorder in a newborn with down syndrome treated with rasburicase for the risk of development of tumor lysis syndrome: A case report. J Med Case Rep (2011) 0.85
Down syndrome-associated haematopoiesis abnormalities created by chromosome transfer and genome editing technologies. Sci Rep (2014) 0.81
Developmental differences in IFN signaling affect GATA1s-induced megakaryocyte hyperproliferation. J Clin Invest (2013) 0.81
Acute megakaryoblastic leukemia with acquired trisomy 21 and GATA1 mutations in phenotypically normal children. Eur J Pediatr (2014) 0.80
The Skin as an Early Expression of Malignancies in the Neonatal Age: A Review of the Literature and a Case Series. Biomed Res Int (2015) 0.79
Transient Myeloproliferative Disorder and Down Syndrome: Is there a link? Sultan Qaboos Univ Med J (2012) 0.77
The impact of trisomy 21 on foetal haematopoiesis. Blood Cells Mol Dis (2013) 0.76
Unbalanced chromosome 1 abnormalities leading to partial trisomy 1q in four infants with Down syndrome and acute megakaryocytic leukemia. Mol Cytogenet (2009) 0.76
Early lineage priming by trisomy of erg leads to myeloproliferation in a down syndrome model. PLoS Genet (2015) 0.76
Sometimes it is better to wait: First Italian case of a newborn with transient abnormal myelopoiesis and a favorable prognosis. Oncol Lett (2016) 0.75
GATA factor mutations in hematologic disease. Blood (2017) 0.75
Down syndrome with different hematological manifestations: a short series of 3 cases with review of literature. Indian J Hematol Blood Transfus (2012) 0.75
Down syndrome and leukemia: insights into leukemogenesis and translational targets. Transl Pediatr (2015) 0.75
Down syndrome with transient myeloproliferative disorder and Beta-thalassemia major. Indian J Hematol Blood Transfus (2014) 0.75
Transient Abnormal Myelopoiesis and AML in Down Syndrome: an Update. Curr Hematol Malig Rep (2016) 0.75
Myeloid Proliferations Associated with Down Syndrome. J Hematop (2014) 0.75
Transient leukaemia: leukaemia or leukaemoid? A diagnostic dilemma. Indian J Hematol Blood Transfus (2011) 0.75
Predispositions to Leukemia in Down Syndrome and Other Hereditary Disorders. Curr Treat Options Oncol (2017) 0.75
Minimal residual disease-directed therapy for childhood acute myeloid leukaemia: results of the AML02 multicentre trial. Lancet Oncol (2010) 3.76
Categorizing the stage of glaucoma from pre-diagnosis to end-stage disease. Am J Ophthalmol (2006) 3.66
Dysfunctional tear syndrome: a Delphi approach to treatment recommendations. Cornea (2006) 3.18
Utility assessment among patients with dry eye disease. Ophthalmology (2003) 2.71
Evaluation of quality-control criteria for microarray gene expression analysis. Clin Chem (2004) 2.28
Randomized use of cyclosporin A (CsA) to modulate P-glycoprotein in children with AML in remission: Pediatric Oncology Group Study 9421. Blood (2005) 2.24
Massive evolution of the immunoglobulin heavy chain locus in children with B precursor acute lymphoblastic leukemia. Blood (2012) 2.17
Natural history of transient myeloproliferative disorder clinically diagnosed in Down syndrome neonates: a report from the Children's Oncology Group Study A2971. Blood (2011) 1.81
Incidence and treatment of potentially lethal diseases in transient leukemia of Down syndrome: Pediatric Oncology Group Study. J Pediatr Hematol Oncol (2002) 1.78
Congenital abnormalities and childhood cancer. Cancer (2005) 1.78
VAMP and low-dose, involved-field radiation for children and adolescents with favorable, early-stage Hodgkin's disease: results of a prospective clinical trial. J Clin Oncol (2002) 1.76
One- and two-stage designs for stratified phase II clinical trials. Stat Med (2005) 1.70
A multicenter, retrospective pilot study of resource use and costs associated with severity of disease in glaucoma. Arch Ophthalmol (2006) 1.64
The incidence and clinical significance of nucleophosmin mutations in childhood AML. Blood (2007) 1.60
GATA1 mutations in transient leukemia and acute megakaryoblastic leukemia of Down syndrome. Blood (2003) 1.57
Association between prenatal pesticide exposures and the generation of leukemia-associated T(8;21). Pediatr Blood Cancer (2007) 1.54
Critical windows of exposure to household pesticides and risk of childhood leukemia. Environ Health Perspect (2002) 1.52
Normal, benign, preneoplastic, and malignant prostate cells have distinct protein expression profiles resolved by surface enhanced laser desorption/ionization mass spectrometry. Clin Cancer Res (2002) 1.51
Differential gene expression, GATA1 target genes, and the chemotherapy sensitivity of Down syndrome megakaryocytic leukemia. Blood (2005) 1.51
Telomerase and the benign and malignant megakaryoblastic leukemias of Down syndrome. J Pediatr Hematol Oncol (2002) 1.50
Outcomes of transplantation in children with primary hepatic malignancy. Pediatr Transplant (2007) 1.48
Risk for leukemia in infants without Down syndrome who have transient myeloproliferative disorder. J Pediatr (2006) 1.48
Oxidation of glutathione peroxidase-deficient red cells by organic peroxides. Blood (2002) 1.46
Human herpesvirus 7 in pediatric hematopoietic stem cell transplantation. Pediatr Blood Cancer (2007) 1.46
CD36 (thrombospondin receptor) expression in childhood acute megakaryoblastic leukemia: in vitro drug sensitivity and outcome. Leuk Lymphoma (2006) 1.45
A basic classification and a comprehensive examination of pediatric myeloproliferative syndromes. J Pediatr Hematol Oncol (2005) 1.42
GATA1, cytidine deaminase, and the high cure rate of Down syndrome children with acute megakaryocytic leukemia. J Natl Cancer Inst (2005) 1.41
Gene expression profiles at diagnosis in de novo childhood AML patients identify FLT3 mutations with good clinical outcomes. Blood (2004) 1.41
Adult ovarian retinoblastoma genomic profile distinct from prior childhood eye tumor. Arch Ophthalmol (2011) 1.39
Origins of leukaemia in children with Down syndrome. Nat Rev Cancer (2005) 1.35
Setting research priorities to reduce mortality and morbidity of childhood diarrhoeal disease in the next 15 years. PLoS Med (2013) 1.34
Comparative analysis of different approaches to measure treatment response in acute myeloid leukemia. J Clin Oncol (2012) 1.30
Down syndrome and malignancies: a unique clinical relationship: a paper from the 2008 william beaumont hospital symposium on molecular pathology. J Mol Diagn (2009) 1.29
Final results of a prospective clinical trial with VAMP and low-dose involved-field radiation for children with low-risk Hodgkin's disease. J Clin Oncol (2007) 1.28
Outcome and staging evaluation in malignant germ cell tumors of the ovary in children and adolescents: an intergroup study. J Pediatr Surg (2004) 1.28
Impact of disease risk on efficacy of matched related bone marrow transplantation for pediatric acute myeloid leukemia: the Children's Oncology Group. J Clin Oncol (2008) 1.27
Utility assessment to measure the impact of dry eye disease. Ocul Surf (2006) 1.27
Long-term treatment of Hashimoto's encephalopathy. J Neuropsychiatry Clin Neurosci (2006) 1.25
Anthracyclines cause endothelial injury in pediatric cancer patients: a pilot study. J Clin Oncol (2006) 1.24
Monosomy 7 and deletion 7q in children and adolescents with acute myeloid leukemia: an international retrospective study. Blood (2007) 1.23
RUNX1 regulates phosphoinositide 3-kinase/AKT pathway: role in chemotherapy sensitivity in acute megakaryocytic leukemia. Blood (2009) 1.22
A global need for affordable neonatal jaundice technologies. Semin Perinatol (2011) 1.20
Meta-analysis of randomized controlled trials of prophylactic granulocyte colony-stimulating factor and granulocyte-macrophage colony-stimulating factor after autologous and allogeneic stem cell transplantation. J Clin Oncol (2006) 1.19
Mutational spectrum at GATA1 provides insights into mutagenesis and leukemogenesis in Down syndrome. Blood (2009) 1.18
Cardiomyopathy in children with Down syndrome treated for acute myeloid leukemia: a report from the Children's Oncology Group Study POG 9421. J Clin Oncol (2008) 1.15
Prenatal origin of GATA1 mutations may be an initiating step in the development of megakaryocytic leukemia in Down syndrome. Blood (2004) 1.13
Phase 2 trial of clofarabine in combination with etoposide and cyclophosphamide in pediatric patients with refractory or relapsed acute lymphoblastic leukemia. Blood (2011) 1.12
Mechanisms of synergistic antileukemic interactions between valproic acid and cytarabine in pediatric acute myeloid leukemia. Clin Cancer Res (2010) 1.11
Medication compliance and disease exacerbation in patients with asthma: a retrospective study of managed care data. Ann Allergy Asthma Immunol (2006) 1.11
Effect of polymorphisms in folate-related genes on in vitro methotrexate sensitivity in pediatric acute lymphoblastic leukemia. Blood (2005) 1.10
The role of cytotoxic therapy with hematopoietic stem cell transplantation in the therapy of acute myeloid leukemia in children: an evidence-based review. Biol Blood Marrow Transplant (2007) 1.10
New insights into Notch1 regulation of the PI3K-AKT-mTOR1 signaling axis: targeted therapy of γ-secretase inhibitor resistant T-cell acute lymphoblastic leukemia. Cell Signal (2013) 1.07
The role of cytidine deaminase and GATA1 mutations in the increased cytosine arabinoside sensitivity of Down syndrome myeloblasts and leukemia cell lines. Cancer Res (2004) 1.07
Comparable long-term survival after unrelated and HLA-matched sibling donor hematopoietic stem cell transplantations for acute leukemia in children younger than 18 months. J Clin Oncol (2006) 1.06
High frequency of leukemic clones in newborn screening blood samples of children with B-precursor acute lymphoblastic leukemia. Blood (2002) 1.05
Risk-adapted, combined-modality therapy with VAMP/COP and response-based, involved-field radiation for unfavorable pediatric Hodgkin's disease. J Clin Oncol (2004) 1.05
Panobinostat enhances cytarabine and daunorubicin sensitivities in AML cells through suppressing the expression of BRCA1, CHK1, and Rad51. PLoS One (2013) 1.03
Randomized, controlled trial of standard, large-capacity versus jumbo biopsy forceps for polypectomy of small, sessile, colorectal polyps. Gastrointest Endosc (2012) 1.02
Treatment of unfavorable childhood Hodgkin's disease with VEPA and low-dose, involved-field radiation. J Clin Oncol (2002) 1.01
Evaluation of a linear amplification method for small samples used on high-density oligonucleotide microarray analysis. Anal Biochem (2004) 1.00
Gemtuzumab ozogamicin can reduce minimal residual disease in patients with childhood acute myeloid leukemia. Cancer (2013) 0.98
Prenatal origin of childhood acute myeloid leukemias harboring chromosomal rearrangements t(15;17) and inv(16). Blood (2003) 0.97
Pediatric-type nodal follicular lymphoma: an indolent clonal proliferation in children and adults with high proliferation index and no BCL2 rearrangement. Blood (2012) 0.97
The effects of disruption of genes for peroxiredoxin-2, glutathione peroxidase-1, and catalase on erythrocyte oxidative metabolism. Free Radic Biol Med (2009) 0.96
Anemia, transfusions and hospital outcomes among critically ill patients on prolonged acute mechanical ventilation: a retrospective cohort study. Crit Care (2008) 0.95
Retroperitoneal malignant peripheral nerve sheath tumor: evaluation with serial FDG-PET. Clin Nucl Med (2004) 0.95
Rituximab therapy for multisystem autoimmune diseases in pediatric patients. J Pediatr (2003) 0.95
Concurrent treatment of steroid-related mood and psychotic symptoms with risperidone. Pediatrics (2010) 0.94
Transcriptional regulation of the cystathionine-beta -synthase gene in Down syndrome and non-Down syndrome megakaryocytic leukemia cell lines. Blood (2002) 0.94
Antimetabolite-based therapy in childhood T-cell acute lymphoblastic leukemia: a report of POG study 9296. Pediatr Blood Cancer (2006) 0.94
Cost of patients with primary open-angle glaucoma: a retrospective study of commercial insurance claims data. Ophthalmology (2007) 0.93
Parent communication and child pain and distress during painful pediatric cancer treatments. Soc Sci Med (2006) 0.92
Case records of the Massachusetts General Hospital. Weekly clinicopathological exercises. Case 19-200. A five-day-old girl with leukocytosis and a worsening rash from birth. N Engl J Med (2003) 0.91
Notch1 receptor regulates AKT protein activation loop (Thr308) dephosphorylation through modulation of the PP2A phosphatase in phosphatase and tensin homolog (PTEN)-null T-cell acute lymphoblastic leukemia cells. J Biol Chem (2013) 0.91
Glaucoma in the United States and europe: predicting costs and surgical rates based upon stage of disease. J Glaucoma (2007) 0.91
Development and validation of a single-cell network profiling assay-based classifier to predict response to induction therapy in paediatric patients with de novo acute myeloid leukaemia: a report from the Children's Oncology Group. Br J Haematol (2013) 0.91
Class I and class II histone deacetylases are potential therapeutic targets for treating pancreatic cancer. PLoS One (2012) 0.91
Complementary therapies for children undergoing stem cell transplantation: report of a multisite trial. Cancer (2010) 0.90
Melatonin cytotoxicity in human leukemia cells: relation with its pro-oxidant effect. Fundam Clin Pharmacol (2006) 0.90
CHK1 plays a critical role in the anti-leukemic activity of the wee1 inhibitor MK-1775 in acute myeloid leukemia cells. J Hematol Oncol (2014) 0.90